Advertisement

Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant)

  • Claudia Mendoza-Pinto
  • Mario García-Carrasco
  • Ricard CerveraEmail author
Antiphospholipid Syndrome (S Zuily, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Antiphospholipid Syndrome

Abstract

Purpose of Review

The antiphospholipid syndrome (APS) is characterized by the development of thrombotic events and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). An infectious etiology for this syndrome has been postulated. The present review is aimed to summarize recent evidence about the role of infections and vaccines in the pathogenesis of the APS (including its catastrophic variant).

Recent Findings

There is an increased risk of developing aPL in various infections, particularly in viral infections. The most frequent infection related to aPL has been hepatitis C virus. These antibodies may be associated with thromboembolic events, including catastrophic APS. There is a link between vaccinations, such as the tetanus toxoid and aPL, due to molecular mimicry between the two molecules.

Summary

Accumulated evidence supports that the presence of aPL is associated with a variety of infections, including viruses, bacteria, fungi, and parasites, and the main mechanism to explain this correlation is molecular mimicry. Moreover, a link between vaccinations, such as the tetanus toxoid, and APS has also been described.

Keywords

Antiphospholipid syndrome Infections Vaccines Thrombosis 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMedGoogle Scholar
  2. 2.
    Pangborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med [Internet]. SAGE Publications. 1941;48:484–6.  https://doi.org/10.3181/00379727-48-13365P.CrossRefGoogle Scholar
  3. 3.
    Lynch FW, Boynton RE KA. False positive serologic reactions for syphilis: due to smallpox vaccinations (vaccinia). J Am Med Assoc [Internet]. 1941;117:591–595. Available from: doi: https://doi.org/10.1001/jama.1941.02820340013005 CrossRefGoogle Scholar
  4. 4.
    Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol. 1984;56:193–9.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.CrossRefPubMedGoogle Scholar
  6. 6.
    Juby AG, Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med. 1998;21:4–11.PubMedGoogle Scholar
  7. 7.
    Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med. 1990;20:231–6.CrossRefGoogle Scholar
  8. 8.
    Asherson RA, Cervera R. “Primary”, “secondary” and other variants of the antiphospholipid syndrome. Lupus. 1994;3:293–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni P-L. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. 2006. p. 2–6.Google Scholar
  10. 10.
    Cacoub P, Musset L, Amoura Z, Guilani P, Chabre H, Lunel F, et al. Anticardiolipin, anti-beta2-glycoprotein I, and antinucleosome antibodies in hepatitis C virus infection and mixed cryoglobulinemia. Multivirc Group J Rheumatol. 1997;24:2139–44.PubMedGoogle Scholar
  11. 11.
    • Huh JY, Yi DY, Hwang SG, Choi JJ, Kang MS. Characterization of antiphospholipid antibodies in chronic hepatitis B infection. Korean J Hematol. 2011, 46:36–40. Article that describes a novel technique that differentiates between antiphospholipid syndrome and asymptomatic antiphospholipid antibody carriers or patients with infectious diseases.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2018;27:572–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Castanon A, Pierre G, Willis R, Harris EN, Papalardo E, Romay-Penabad Z, et al. Performance evaluation and clinical associations of immunoassays that detect antibodies to negatively charged phospholipids other than Cardiolipin. Am J Clin Pathol. 2018;29:401–11.CrossRefGoogle Scholar
  14. 14.
    Roggenbuck D, Borghi MO, Somma V, Buttner T, Schierack P, Hanack K, et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016;18:111.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    • Palomo I, Alarcon M, Sepulveda C, Pereira J, Espinola R, Pierangeli S. Prevalence of antiphospholipid and antiplatelet antibodies in human immunodeficiency virus (HIV)-infected Chilean patients. J Clin Lab Anal. 2003;17:209–15. A systematic review and meta-analysis of articles linking viral hepatitis and antiphospholipid antibodies.CrossRefPubMedGoogle Scholar
  16. 16.
    • Brew BJ, Miller J. Human immunodeficiency virus type 1-related transient neurological deficits. Am J Med. 1996, 101:257–61. A systematic review of articles linking viral infection and antiphospholipid antibodies.CrossRefPubMedGoogle Scholar
  17. 17.
    Dalekos GN, Kistis KG, Boumba DS, Voulgari P, Zervou EK, Drosos AA, et al. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol. 2000;12:67–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Zachou K, Liaskos C, Christodoulou DK, Kardasi M, Papadamou G, Gatselis N, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Investig. 2003;33:161–8.CrossRefGoogle Scholar
  19. 19.
    Sene D, Piette J-C, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008;7:272–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Ambrosino P, Lupoli R, Tarantino P, Di Minno A, Tarantino L, Di Minno MND. Viral hepatitis and anti-phospholipid antibodies positivity: a systematic review and meta-analysis. Dig Liver Dis. 2015;47:478–87.CrossRefPubMedGoogle Scholar
  21. 21.
    Alessandri C, Bombardieri M, Di Prospero L, Conigliaro P, Conti F, Labbadia G, et al. Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. Clin Exp Immunol. 2005;140:173–80.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016;25:1520–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Cole FS, Brusch JL, Talarico L. A circulating anticoagulant in lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1979;47:121–5.PubMedGoogle Scholar
  24. 24.
    de Larranaga GF, Forastiero RR, Martinuzzo ME, Carreras LO, Tsariktsian G, Sturno MM, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9:594–600.CrossRefPubMedGoogle Scholar
  25. 25.
    Ilarraza H, Marquez MF, Alcocer A, Banales JL, Nava AH, Reyes PA. Anticardiolipin antibodies are not associated with rheumatic heart disease. Lupus. 2001;10:873–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Ordi-Ros J, Selva-O’Callaghan A, Monegal-Ferran F, Monasterio-Aspiri Y, Juste-Sanchez C, Vilardell-Tarres M. Prevalence, significance, and specificity of antibodies to phospholipids in Q fever. Clin Infect Dis. 1994;18:213–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Million M, Bardin N, Bessis S, Nouiakh N, Douliery C, Edouard S, et al. Thrombosis and antiphospholipid antibody syndrome during acute Q fever: a cross-sectional study. Medicine (Baltimore). 2017;96:e7578.CrossRefGoogle Scholar
  28. 28.
    •• Ascer E, Marques M, Gidlund M. M pneumoniae infection, pulmonary thromboembolism and antiphospholipid antibodies. BMJ Case Rep. 2011;pii: bcr1220103561. A systematic review of articles linking viral infections and antiphospholipid antibodies.Google Scholar
  29. 29.
    Greco TPJ, Conti-Kelly AM, Greco TP. Antiphospholipid antibodies in patients with purported “chronic Lyme disease”. Lupus. 2011;20:1372–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84:4203–8.PubMedGoogle Scholar
  31. 31.
    Cotticelli L, Borrelli M, D’Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006;16:274–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Medina G, Briones-Garcia E, Cruz-Dominguez MP, Florez-Durante OI, Jara LJ. Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: thrombosis recurrence. Autoimmun Rev. 2017;16:352–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Blank M, Krause I, Magrini L, Spina G, Kalil J, Jacobsen S, et al. Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology (Oxford). 2006;45:833–41.CrossRefGoogle Scholar
  34. 34.
    da Silva F, de Carvalho J. Rheumatic fever associated with antiphospholipid syndrome: systematic review. J Immunol Res. 2014;2014:614591.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Figueroa F, Berrios X, Gutierrez M, Carrion F, Goycolea JP, Riedel I, et al. Anticardiolipin antibodies in acute rheumatic fever. J Rheumatol. 1992;19:1175–80.PubMedGoogle Scholar
  36. 36.
    de Carvalho JF, Goldenstein-Schainberg C. Lack of antiphospolipid antibodies in long-term cardiac rheumatic fever. Rheumatol. Int. 2012. p. 2951.Google Scholar
  37. 37.
    Skouri H, Gandouz R, Kraiem I, Harrabi I, Ben SM. Antibodies to anionic phospholipids and cofactors in kala-azar. Comparative study with malaria, toxoplasmosis and “autoimmune diseases”. Clin Exp Rheumatol. 2008;26:894–902.PubMedGoogle Scholar
  38. 38.
    Tavakoli M, Roghaee S, Soheilian R, Soheilian M. Antiphospholipid syndrome following toxoplasma retinochoroiditis. Ocul Immunol Inflamm. 2011;19:311–3.CrossRefPubMedGoogle Scholar
  39. 39.
    Santiago M, Martinelli R, Ko A, Reis EA, Fontes RD, Nascimento EG, et al. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and kala-azar. Clin Exp Rheumatol. 2001;19:425–30.PubMedGoogle Scholar
  40. 40.
    •• Cervera R, Font J, Gomez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205–9. A comprehensive review of the link between infectious diseases and the catastrophic antiphospholipid syndrome.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cervera R, Rodriguez-Pinto I, Colafrancesco S, Conti F, Valesini G, Rosario C, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev. 2014. p. 699–707.CrossRefPubMedGoogle Scholar
  42. 42.
    Rodriguez-Pinto I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016;15:1120–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Betancur J-F, Navarro E-P, Echeverry A, Moncada PA, Canas CA, Tobon GJ. Hyperferritinemic syndrome: Still’s disease and catastrophic antiphospholipid syndrome triggered by fulminant Chikungunya infection: a case report of two patients. Clin Rheumatol. 2015;34:1989–92.CrossRefPubMedGoogle Scholar
  44. 44.
    Betancur J-F, Navarro EP, Bravo Bonilla JH, Cortes AD, Velez JD, Echeverry A, et al. Catastrophic antiphospholipid syndrome triggered by fulminant chikungunya infection in a patient with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2016;68:1044.CrossRefGoogle Scholar
  45. 45.
    Espinosa G, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol. 2007. p. 923–6.Google Scholar
  46. 46.
    Bucciarelli S, Espinosa G, Cervera R. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus. 2009;18:905–12.CrossRefPubMedGoogle Scholar
  47. 47.
    Inic-Kanada A, Stojanovic M, Zivkovic I, Kosec D, Micic M, Petrusic V, et al. Murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with beta2-glycoprotein I: its characteristics and role in molecular mimicry. Am J Reprod Immunol. 2009;61:39–51.CrossRefPubMedGoogle Scholar
  48. 48.
    Zivkovic I, Stojanovic M, Petrusic V, Inic-Kanada A, Dimitrijevic L. Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice. Am J Reprod Immunol. 2011;65:492–502.CrossRefPubMedGoogle Scholar
  49. 49.
    Bizjak M, Bruck O, Kanduc D, Praprotnik S, Shoenfeld Y. Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Semin Hematol. 2016;53(Suppl 1):S48–50.CrossRefPubMedGoogle Scholar
  50. 50.
    de Medeiros DM, Silva CA, Bueno C, Ribeiro ACM. Viana V dos ST, Carvalho JF, et al. Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production? Lupus. 2014;23:1412–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Vista ES, Crowe SR, Thompson LF, Air GM, Robertson JM, Guthridge JM, et al. Influenza vaccination can induce new-onset anticardiolipins but not beta2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus. 2012;21:168–74.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Claudia Mendoza-Pinto
    • 1
    • 2
  • Mario García-Carrasco
    • 1
    • 2
  • Ricard Cervera
    • 3
    Email author
  1. 1.Systemic Autoimmune Diseases Research Unit, UMAE CMN Manuel Avila CamachoInstituto Mexicano del Seguro SocialPueblaMexico
  2. 2.Immunology and Rheumatology, Medical SchoolBenemérita Universidad Autónoma de PueblaPueblaMexico
  3. 3.Department of Autoimmune DiseasesHospital ClinicBarcelonaSpain

Personalised recommendations